Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.70 Bil Enterprise Value: 10.12 Bil PE Ratio: 113.19 PB Ratio: 2.90 GF Score: 82/100

Qiagen NV at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 09:30PM GMT
Release Date Price: €32.43 (-0.13%)
Ruizhi Qin
JP Morgan Chase & Co, Research Division - Analyst

Good afternoon. My name is Julia Qin. I work on the life science tools and diagnostics team at JPMorgan. It's my great pleasure to welcome you to our next company presentation today by QIAGEN.

As a reminder, there's a breakout after this session in the Olympic Room right down the hallway.

And with that, I'll turn it over to Thierry. Welcome.

Thierry Bernard
QIAGEN N.V. - Interim CEO, Senior VP & Head of Molecular Diagnostics Business Area

Thank you so much, and good afternoon, and thanks for this opportunity to assess and highlight the situation of QIAGEN starting 2020 after what I could qualify as an eventful, I would say, 2019. And what I'd like to insist on, and we are really striving the company now to execute on what we consider to be a very differentiated Sample to Insight portfolio. If I had 3 takeaways for today, I would insist on the following. As I said before, despite the different events that we have been through, and I will come back to that in '19, I believe

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot